-
Mashup Score: 4Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients - 9 month(s) ago
Emapalumab is a monoclonal antibody targeting interferon gamma (IFN-g) and is currently FDA-approved for refractory, recurrent, or progressive hemophagocytic ly
Source: ashpublications.orgCategories: Hematologists1, Latest HeadlinesTweet
-
Mashup Score: 1
Abstract. Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk fact
Source: academic.oup.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Longitudinal Serum Proteomics Characterization of CD19-CAR-T Cell Therapy for B-Cell Malignancies - 9 month(s) ago
Chimeric antigen receptor (CAR)-modified T cells have demonstrated remarkable efficacy in treating B-cell leukemia. However, treated patients may potentially develop side effects, such as cytokine release syndrome (CRS), the mechanisms of which remain unclear. Here, we collected 43 serum samples from eight patients with B-cell acute lymphoblastic leukemia (B-ALL) before and five time points after CD19-specific CAR-T cell treatment. Using TMTpro 16-plex-based quantitative proteomics, we quantified 1151 proteins and profiled the longitudinal proteomes analysis of each patient. Seven days after therapy, we found the most dysregulated inflammatory proteins. Lipid metabolism proteins, including APOA1, decreased after therapy, reached their minimum after 7 days, and then gradually recovered. Hence, APOA1 has been selected as a potential biomarker of the CRS disease progression. Furthermore, we identified CD163 as a potential biomarker of CRS severity. These two biomarkers were successfully v
Source: pubs.acs.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Single-cell RNA analysis reveals cell-intrinsic functions of CAR-T cells correlating with response in a phase II study of lymphoma patients - 9 month(s) ago
Abstract. Purpose: Although CD19 CAR-T cell therapy has shown remarkable success in B cell malignancies, a substantial fraction of patients does not obtain a long-term clinical response. This could be influenced by the quality of the individual CAR-T infusion product. To shed some light on this, clinical outcome was correlated to characteristics of CAR-T cell infusion products. Patients and Methods: In this phase II study patients with B cell lymphoma (n=23) or leukemia (n=1) received one or two infusions of third generation CD19-directed CAR-T cells (2×108/m2). The clinical trial was registered at clinicaltrials.gov: NCT03068416. We investigated the transcriptional profile of individual third generation CD19 CAR-T infusion products using targeted single-cell RNA sequencing and multicolor flow cytometry. Results: Two CAR-T infusions were not better than one in the settings used in this study. As for the CAR-T infusion products we found that effector-like CD8+CAR-T cells with a high pol
Source: aacrjournals.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma - 10 month(s) ago
Follicular lymphoma (FL) is traditionally considered treatable but incurable. In March 2021, the US Food and Drug Administration approved the use of c…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The Role of Chimeric Antigen Receptor T-Cell Therapy in the Era of Bispecific Antibodies - 11 month(s) ago
Section snippetsKey points•Chimeric antigen receptor (CAR) T-cell therapy and bispecific antibodies have led to significant advancements in the management of relapsed/refractory blood cancers with several FDA approved products for multiple myeloma, non-Hodgkin lymphoma and B-cell lymphoblastic leukemia.•In the absence of head-to-head comparisons of CAR T-cell therapy versus bispecific antibodies,…
Source: www.sciencedirect.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 5
– First CRISPR gene-editing filings to be accepted for review by FDA – – FDA grants Priority Review for severe sickle cell disease (SCD) and Standard Review for transfusion-dependent beta thalassemia (TDT) – – PDUFA target action date of December 8, 2023 , for SCD and March 30, 2024 , for TDT –
Source: CRISPR TherapeuticsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3
Abstract RE-MIND2 (NCT04697160) compared patient outcomes from the L-MIND (NCT02399085) trial of tafasitamab+lenalidomide with those of patients treated with other therapies for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who are autologous stem cell transplant ineligible. We present outcomes data for three pre-specified treatments not assessed in the primary analysis. Data…
Source: SpringerLinkCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2
Key Points. Chronic stimulation of CD28-based CARs drives T cells to become exhausted, while 41BB-based CARs direct a novel state of T cell dysfunction41BB-driv
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Circulating Tumor DNA Adds Specificity to PET following Axicabtagene Ciloleucel in Large B-cell Lymphoma - 1 year(s) ago
Key Points. MTV and ctDNA did not correlate in patients with LBCL with evidence of disease 1 month post axi-cel, suggesting ongoing therapy response.MTV and ctD
Source: American Society of HematologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
RT @CARTTherapy: Emapalumab for the treatment of Refractory Cytokine Release Syndrome in Pediatric Patients https://t.co/CU2I3YVz5g #CART…